- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
- PR Newswire
- News
Warner Chilcott Reports the Death of Its Director James Andress
—
ST. DAVID'S, BermudaMarch 14ST. DAVID'S, Bermuda, March 14 /PRNewswire/ --
It is with a profound sense of loss that Warner Chilcott Limited (Nasdaq: WCRX) reports today that Mr. James G. Andress, a director of the Company, died on Tuesday, March 11, 2008.
Roger Boissonneault, Chief Executive Officer, President and Director of Warner Chilcott Limited, issued the following statement:
"We report the loss of Jim Andress with great sadness. Jim was instrumental in the development of this Company. His thoughtful guidance and counsel will be sorely missed. Our deepest sympathies go out to Jim's family."
Mr. Andress was appointed to the Company's board of directors in August of 2006, and at the time of his passing he also served as the co-chairman of the audit committee of the board of directors. Mr. Andress was a former Chairman of the Pharmaceuticals Group, Beecham Group, plc, former Chairman, Healthcare Products and Services of SmithKline Beecham, plc and former President and Chief Operating Officer of Sterling Drug, Inc. From 1996 to 2000, Mr. Andress served as Chairman and Chief Executive Officer of Warner Chilcott PLC (acquired by the Company's predecessor in September 2000). Mr. Andress also served on the board of directors of Sepracor, Inc., XOMA Ltd. and Allstate Insurance Company.
About Warner Chilcott
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G
Read more on http://www.warnerchilcott.com.
Web site: http://www.warnerchilcott.com
Warner Chilcott Limited
Rochelle Fuhrmann, Investor Relations, +1-973-442-3281, or rfuhrmann@wcrx.com, Warner Chilcott Limited
Related Pharmalicensing company profiles
Related news
Related News
- FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
- Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
- Cervical Cancer Charity Welcomes Department of Health's Announcement About HPV Vaccine
- Laureate Pharma Reports Record Growth for 2007
- GeneNews Launches World's First Blood Test for Colorectal Cancer Screening
- Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
- Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
- WHO Creates New Surgical Tool to Make Operations Safer Everywhere
- WHO Creates New Surgical Tool to Make Operations Safer Everywhere
- Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
Latest News
- Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
- Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
- Schofield Publishing Enters the Newsletter Market
- Susan G. Komen for the Cure(R) Encourages Runners to Join 'Team Marathon' and Help End Breast Cancer Forever
- Unite Health Members Canvassed on Industrial Action Over 'Derisory' Pay
- Senetek Launches Pyratine-6(TM)
- Agendia Launches TargetPrint(R) for Breast Cancer Patients
- The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
- Movianto Supports Pinnacle Biologics' Market Entry Into Europe
- ScienceDirect Increases Researcher Productivity With Document Download Manager
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us